Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial

Open access

Abstract

Objective: Hydrothermal duodenal mucosal resurfacing (DMR) is a safe, outpatient endoscopic procedure. REVITA-2, a double-blind, superiority randomised controlled trial, investigates safety and efficacy of DMR using the single catheter Revita system (Revita DMR (catheter and system)), on glycaemic control and liver fat content in type 2 diabetes (T2D). Design: Eligible patients (haemoglobin A1c (HbA1c) 59–86 mmol/mol, body mass index≥24 and ≤40 kg/m 2 , fasting insulin >48.6 pmol/L, ≥1 oral antidiabetic medication) enrolled in Europe and Brazil. Primary endpoints were safety, change from baseline in HbA1c at 24 weeks, and liver MRI proton-density fat fraction (MRI-PDFF) at 12 weeks. Results: Overall mITT (DMR n=56; sham n=52), 24 weeks post DMR, median (IQR) HbA1c change was −10.4 (18.6) mmol/mol in DMR group versus −7.1 (16.4) mmol/mol in sham group (p=0.147). In patients with baseline liver MRI-PDFF >5% (DMR n=48; sham n=43), 12-week post-DMR liver-fat change was −5.4 (5.6)% in DMR group versus −2.9 (6.2)% in sham group (p=0.096). Results from prespecified interaction testing and clinical parameter assessment showed heterogeneity between European (DMR n=39; sham n=37) and Brazilian (DMR n=17; sham n=16) populations (p=0.063); therefore, results were stratified by region. In European mITT, 24 weeks post DMR, median (IQR) HbA1c change was –6.6 mmol/mol (17.5 mmol/mol) versus –3.3 mmol/mol (10.9 mmol/mol) post-sham (p=0.033); 12-week post-DMR liver-fat change was –5.4% (6.1%) versus –2.2% (4.3%) post-sham (p=0.035). Brazilian mITT results trended towards DMR benefit in HbA1c, but not liver fat, in context of a large sham effect. In overall PP, patients with high baseline fasting plasma glucose ((FPG)≥10 mmol/L) had significantly greater reductions in HbA1c post-DMR versus sham (p=0.002). Most adverse events were mild and transient. Conclusions: DMR is safe and exerts beneficial disease-modifying metabolic effects in T2D with or without non-alcoholic liver disease, particularly in patients with high FPG. Trial registration number: NCT02879383

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2020-323608

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Patient disposition. Between 1 March 2017, and 15 December 2018, 109 of 359 patients assessed for eligibility were randomised. One patient at a European study site did not receive treatment due to oesophageal varicesa; therefore, the modified intention-to-treat (mITT) population included 108 patients—75 in Europe (39 to duodenal mucosal resurfacing (DMR) and 36 to sham) and 33 in Brazil (17 to DMR and 16 to sham). Prespecified assessments of normality and homogeneity (see the Methods section for details) revealed that the European and Brazilian populations were not poolable. Therefore, all efficacy analyses were stratified into two populations (Europe and Brazil). aThe one patient who withdrew and did not receive treatment was followed for safety, but not efficacy. Last completed visit was at week 4a, week 21 (phone call)b, and day 7 (phone call)d. PP, per protocol.
Figure 1 Patient disposition. Between 1 March 2017, and 15 December 2018, 109 of 359 patients assessed for eligibility were randomised. One patient at a European study site did not receive treatment due to oesophageal varicesa; therefore, the modified intention-to-treat (mITT) population included 108 patients—75 in Europe (39 to duodenal mucosal resurfacing (DMR) and 36 to sham) and 33 in Brazil (17 to DMR and 16 to sham). Prespecified assessments of normality and homogeneity (see the Methods section for details) revealed that the European and Brazilian populations were not poolable. Therefore, all efficacy analyses were stratified into two populations (Europe and Brazil). aThe one patient who withdrew and did not receive treatment was followed for safety, but not efficacy. Last completed visit was at week 4a, week 21 (phone call)b, and day 7 (phone call)d. PP, per protocol.CC BY-NC · PubMed Central
Figure 2 Post-hoc analysis of change in haemoglobin A1c (HbA1c) levels and liver MRI proton density fat fraction (MRI-PDFF) stratified by baseline fasting plasma glucose (FPG) level status (per-protocol (PP) populations). Median HbA1c per cent change from baseline to 24 weeks (duodenal mucosal resurfacing (DMR) versus sham procedure) in the overall (A), European (C) and Brazilian (E) PP patients with baseline FPG ≥10 mmol/L compared with patients with baseline FPG <10 mmol/L. In patients with baseline liver MRI-PDFF >5%, median liver MRI-PDFF per cent change from baseline to 12 weeks (DMR vs sham procedure) in the overall (B), European (D), and Brazilian (F) PP patients with baseline FPG ≥10 mmol/L compared with FPG <10 mmol/L. Treatment comparison of one-sided p value based on analysis of covariance model with multiple imputation on the rank values (modified ridit scores). Via multiple imputation, analysis is based on all patients in the population of interest. The overall PP population includes patients from both European and Brazilian study sites. The European PP population consists of patients from Italy, UK, Belgium and Netherlands.
Figure 2 Post-hoc analysis of change in haemoglobin A1c (HbA1c) levels and liver MRI proton density fat fraction (MRI-PDFF) stratified by baseline fasting plasma glucose (FPG) level status (per-protocol (PP) populations). Median HbA1c per cent change from baseline to 24 weeks (duodenal mucosal resurfacing (DMR) versus sham procedure) in the overall (A), European (C) and Brazilian (E) PP patients with baseline FPG ≥10 mmol/L compared with patients with baseline FPG <10 mmol/L. In patients with baseline liver MRI-PDFF >5%, median liver MRI-PDFF per cent change from baseline to 12 weeks (DMR vs sham procedure) in the overall (B), European (D), and Brazilian (F) PP patients with baseline FPG ≥10 mmol/L compared with FPG <10 mmol/L. Treatment comparison of one-sided p value based on analysis of covariance model with multiple imputation on the rank values (modified ridit scores). Via multiple imputation, analysis is based on all patients in the population of interest. The overall PP population includes patients from both European and Brazilian study sites. The European PP population consists of patients from Italy, UK, Belgium and Netherlands.CC BY-NC · PubMed Central
Figure 3 Haemoglobin A1c (HbA1c) levels and liver MRI proton density fat fraction (MRI-PDFF) at 24 weeks post duodenal mucosal resurfacing (DMR) (primary endpoint). Median per cent change in HbA1c levels (DMR vs sham procedure) from baseline to 24 weeks in the European (A) and Brazilian (B) modified intention-to-treat (mITT) and per-protocol (PP) populations. Median absolute per cent change in liver MRI-PDFF (DMR vs sham procedure) from baseline to 24 weeks in patients with baseline MRI-PDFF >5% (*) in the European (C) and Brazilian (D) mITT and PP populations. Treatment comparison one-sided p value based on analysis of covariance model with multiple imputation on the rank values (modified ridit scores). Via multiple imputation, analysis is based on all patients in the population of interest where post rescue values are first set to missing. Data for continuous variables are on non-imputed unadjusted descriptive statistics based on patients with non-missing values.
Figure 3 Haemoglobin A1c (HbA1c) levels and liver MRI proton density fat fraction (MRI-PDFF) at 24 weeks post duodenal mucosal resurfacing (DMR) (primary endpoint). Median per cent change in HbA1c levels (DMR vs sham procedure) from baseline to 24 weeks in the European (A) and Brazilian (B) modified intention-to-treat (mITT) and per-protocol (PP) populations. Median absolute per cent change in liver MRI-PDFF (DMR vs sham procedure) from baseline to 24 weeks in patients with baseline MRI-PDFF >5% (*) in the European (C) and Brazilian (D) mITT and PP populations. Treatment comparison one-sided p value based on analysis of covariance model with multiple imputation on the rank values (modified ridit scores). Via multiple imputation, analysis is based on all patients in the population of interest where post rescue values are first set to missing. Data for continuous variables are on non-imputed unadjusted descriptive statistics based on patients with non-missing values.CC BY-NC · PubMed Central
Figure 4 Clinically meaningful reductions in weight, liver fat and homeostatic model assessment of insulin resistance (HOMA-IR) with duodenal mucosal resurfacing (DMR). Median weight (kg) change from baseline to 24 weeks (DMR vs sham procedure) in the European (A) and Brazilian (B) modified intention-to-treat (mITT) and per-protocol (PP) populations. Median relative liver MRI proton density fat fraction (MRI-PDFF) per cent change from baseline to 12 weeks in patients with baseline MRI-PDFF >5% (*) in the European (C) and Brazilian (D) mITT and PP populations. Median fasting plasma glucose (FPG; millimoles per litre) change from baseline to 24 weeks (DMR vs sham procedure) in the European (E) and Brazilian (F) mITT and PP populations. Median HOMA-IR change from baseline to 12 weeks (DMR vs sham procedure) in the European (G) and Brazilian (H) mITT and PP populations. Data for continuous variables are on non-imputed unadjusted descriptive statistics based on patients with non-missing values. Treatment comparison one-sided p value based on analysis of covariance model on ranks (modified ridit scores) where post rescue values are first set to missing. Last rank carried forward on ranks was used for missing data for FPG levels, weight and HOMA-IR endpoints. HOMA-IR was determined as (FPG * fasting insulin)/135, where FPG levels were measured in millimoles per litre and fasting insulin is measured in picomoles per litre.
Figure 4 Clinically meaningful reductions in weight, liver fat and homeostatic model assessment of insulin resistance (HOMA-IR) with duodenal mucosal resurfacing (DMR). Median weight (kg) change from baseline to 24 weeks (DMR vs sham procedure) in the European (A) and Brazilian (B) modified intention-to-treat (mITT) and per-protocol (PP) populations. Median relative liver MRI proton density fat fraction (MRI-PDFF) per cent change from baseline to 12 weeks in patients with baseline MRI-PDFF >5% (*) in the European (C) and Brazilian (D) mITT and PP populations. Median fasting plasma glucose (FPG; millimoles per litre) change from baseline to 24 weeks (DMR vs sham procedure) in the European (E) and Brazilian (F) mITT and PP populations. Median HOMA-IR change from baseline to 12 weeks (DMR vs sham procedure) in the European (G) and Brazilian (H) mITT and PP populations. Data for continuous variables are on non-imputed unadjusted descriptive statistics based on patients with non-missing values. Treatment comparison one-sided p value based on analysis of covariance model on ranks (modified ridit scores) where post rescue values are first set to missing. Last rank carried forward on ranks was used for missing data for FPG levels, weight and HOMA-IR endpoints. HOMA-IR was determined as (FPG * fasting insulin)/135, where FPG levels were measured in millimoles per litre and fasting insulin is measured in picomoles per litre.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 120

Metadata

Authors
Mingrone, G., van Baar, A. C., Devière, J., Hopkins, D., Moura, E., Cercato, C., Rajagopalan, H., Lopez-Talavera, J. C., White, K., Bhambhani, V., Costamagna, G., Haidry, R., Grecco, E., Galvao Neto, M., Aithal, G., Repici, A., Hayee, B., Haji, A., Morris, A. J., Bisschops, R., Chouhan, M. D., Sakai, N. S., Bhatt, D. L., Sanyal, A. J., & Bergman, J. J. G. H. M.
Affiliations
  • Università Cattolica del Sacro Cuore (IT)
  • Departments of Gastroenterology and Hepatology, Academic Medical Center Amsterdam, Amsterdam, The Netherlands
  • Department of Gastroenterology, Erasme University Hospital, Brussels, Belgium
  • Kings Health Partners (GB)
  • Universidade de São Paulo (BR)
  • Obesity Unit, Department of Endocrinology, Hospital das Clínicas, University of Sao Paulo, Sao Paulo, Brazil
  • Fractyl (United States) (US)
  • Research and Development, Fractyl Laboratories, Inc, Lexington, Massachusetts, USA
  • King's College Hospital (GB)
  • Department of Surgery, ABC University, Medical School, São Paulo, Brazil
  • University of Nottingham (GB)
  • Humanitas University (IT)
  • Glasgow Royal Infirmary (GB)
  • KU Leuven (BE)
  • University College London (GB)
  • Brigham and Women's Hospital (US)
  • Virginia Commonwealth University (US)
  • Amsterdam UMC Location University of Amsterdam (NL)
Corresponding author
Mingrone, Geltrude
Venue
Gut
Publisher
BMJ
Published
2021-02-17
Volume
71
Issue
2
Pages
254-264
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W3131132851
Cited by
120
References
33
Citations by year
2026: 18 · 2025: 32 · 2024: 32 · 2023: 19 · 2022: 11 · 2021: 8
FWCI
13.05
Type
journal article
Language
en
Open access
Locations
  • Gut (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Repository@Nottingham (University of Nottingham) (acceptedVersion, other-oa)
  • Pure Amsterdam UMC (acceptedVersion, cc-by)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
  • Lirias (KU Leuven) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • UCL Discovery (University College London) (submittedVersion)
  • Research Portal (King's College London) (submittedVersion, cc-by-nc)
  • Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by-nc)
  • PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, other-oa)
Funders
Fractyl (N/A)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
type 2 diabetes, glycemic control, HbA1c, liver fat, proton density fat fraction, endoscopic treatment, regional heterogeneity, treatment safety, type 2 diabetes remission, insulin resistance, non-alcoholic fatty liver disease
MeSH terms
Endoscopic Mucosal Resection, Adult, Aged, Diabetes Mellitus, Type 2, Double-Blind Method, Duodenum, Feasibility Studies, Female, Glycated Hemoglobin, Humans, Hyperthermia, Induced, Intestinal Mucosa, Male, Middle Aged, Treatment Outcome, Catheter Ablation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial. https://app.cochat.ai/papers/10.1136/gutjnl-2020-323608
The paper
Mingrone, G., van Baar, A. C., Devière, J., Hopkins, D., Moura, E., Cercato, C., Rajagopalan, H., Lopez-Talavera, J. C., White, K., Bhambhani, V., Costamagna, G., Haidry, R., Grecco, E., Galvao Neto, M., Aithal, G., Repici, A., Hayee, B., Haji, A., Morris, A. J., . . . Bergman, J. J. G. H. M. (2022). Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial. Gut. https://doi.org/10.1136/gutjnl-2020-323608

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.